Literature DB >> 20100496

Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular "pruning".

Alberto d'Onofrio1, Alberto Gandolfi.   

Abstract

In this work we propose to model chemotherapy taking into account the mutual interaction between tumour growth and the development of tumour vasculature. By adopting a simple model for this interaction, and assuming that the efficacy of a drug can be modulated by the vessel density, we study the constant continuous therapy, the periodic bolus-based therapy, and combined therapy in which a chemotherapic drug is associated with an anti-angiogenic agent. The model allows to represent the vessel-disrupting activity of some standard chemotherapic drugs, and shows, in the case of constant continuous drug administration, the possibility of multiple stable equilibria. The multistability suggests an explanation for some sudden losses of control observed during therapy, and for the beneficial effect of vascular "pruning" exerted by anti-angiogenic agents in combined therapy. Moreover, in case of periodic therapies in which the drug amount administered per unit time is constant ("metronomic" delivery), the model predicts a response, as a function of the bolus frequency, significantly influenced by the extent of the anti-angiogenic activity of the chemotherapic drug and by the dependence of the drug efficacy on the vessel density. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100496     DOI: 10.1016/j.jtbi.2010.01.023

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  7 in total

1.  Comparison of simple models of periodic protocols for combined anticancer therapy.

Authors:  Marzena Dołbniak; Andrzej Swierniak
Journal:  Comput Math Methods Med       Date:  2013-04-07       Impact factor: 2.238

2.  Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.

Authors:  Severine Mollard; Joseph Ciccolini; Diane-Charlotte Imbs; Raouf El Cheikh; Dominique Barbolosi; Sebastien Benzekry
Journal:  Oncotarget       Date:  2017-04-04

3.  Optimization of Cancer Treatment in the Frequency Domain.

Authors:  Pascal Schulthess; Vivi Rottschäfer; James W T Yates; Piet H van der Graaf
Journal:  AAPS J       Date:  2019-09-11       Impact factor: 4.009

Review 4.  An Overview of In Vitro, In Vivo, and Computational Techniques for Cancer-Associated Angiogenesis Studies.

Authors:  Heshu Sulaiman Rahman; Bee Ling Tan; Hemn Hassan Othman; Max Stanley Chartrand; Yashwant Pathak; Syam Mohan; Rasedee Abdullah; Noorjahan Banu Alitheen
Journal:  Biomed Res Int       Date:  2020-12-10       Impact factor: 3.411

5.  Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.

Authors:  Katerina D Argyri; Dimitra D Dionysiou; Fay D Misichroni; Georgios S Stamatakos
Journal:  Biol Direct       Date:  2016-03-22       Impact factor: 4.540

6.  Chronic hepatitis B virus and liver fibrosis: A mathematical model.

Authors:  Avner Friedman; Nourridine Siewe
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

7.  Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response.

Authors:  Ahmed El Kaffas; Assaf Hoogi; Jianhua Zhou; Isabelle Durot; Huaijun Wang; Jarrett Rosenberg; Albert Tseng; Hersh Sagreiya; Alireza Akhbardeh; Daniel L Rubin; Aya Kamaya; Dimitre Hristov; Jürgen K Willmann
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.